10-2021

PHARMACEUTICAL POTENTIAL OF LABORATORY GROWN CULTURES OF BLUE-GREEN ALGAE: A COMPREHENSIVE REVIEW AND FUTURE POSSIBILITIES

Rita Chauhan
Abhishek Chauhan
Ashutosh Tripathi
Anuj Ranjan
Subhash C. Chauhan

The University of Texas Rio Grande Valley

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub

Part of the Medicine and Health Sciences Commons

See next page for additional authors

Recommended Citation
Amity Institute of Environmental Sciences, Amity University, Sector-125, Noida, Uttar Pradesh, India, Chauhan, R., Chauhan, A., Amity Institute of Environmental Toxicology, Safety and Management, Amity University, Sector-125, Noida, Uttar Pradesh, India, Tripathi, A., Amity Institute of Environmental Sciences, Amity University, Sector-125, Noida, Uttar Pradesh, India, Ranjan, A., Amity Institute of Environmental Toxicology, Safety and Management, Amity University, Sector-125, Noida, Uttar Pradesh, India, Chauhan, S. C., STCECR, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA, Jindal, T., Amity Institute of Environmental Sciences, Amity University, Sector-125, Noida, Uttar Pradesh, India, & Amity Institute of Environmental Toxicology, Safety and Management, Amity University, Sector-125, Noida, Uttar Pradesh, India. (2021). PHARMACEUTICAL POTENTIAL OF LABORATORY GROWN CULTURES OF BLUE-GREEN ALGAE: A COMPREHENSIVE REVIEW AND FUTURE POSSIBILITIES. Journal of Experimental Biology and Agricultural Sciences, 9(5), 543–571. https://doi.org/10.18006/2021.9(5).543.571

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.
PHARMACEUTICAL POTENTIAL OF LABORATORY GROWN CULTURES OF BLUE-GREEN ALGAE: A COMPREHENSIVE REVIEW AND FUTURE POSSIBILITIES

Ritu Chauhan¹, Abhishek Chauhan²*, Ashutosh Tripathi¹*, Anuj Ranjan², Subhash C. Chauhan³, Tanu Jindal¹,2

¹Amity Institute of Environmental Sciences, Amity University, Sector-125, Noida, Uttar Pradesh, India
²Amity Institute of Environmental Toxicology, Safety and Management, Amity University, Sector-125, Noida, Uttar Pradesh, India
³STCECR, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA

Received – July 26, 2021; Revision – September 29, 2021; Accepted – October 16, 2021
Available Online – October 30, 2021
DOI: http://dx.doi.org/10.18006/2021.9(5).543.571

KEYWORDS
Blue-Green Algae
Biomass
Pharmacologically Important Compound
Biological activities
Discovery
Development

ABSTRACT
COVID-19 pandemic has taught the world researchers the urgent need for new sources and novel pharmaceuticals not only for existing diseases but also for both seasonal epidemics and future pandemics. Pharmaceutical drug discoveries for the past fifty years depended deeply on the procedure of empirical transmission of a huge number of pure bioactive compounds to provide new leads. The screening of extracts or isolating compounds is a common way to discover novel biologically active molecules. Most of the valuable Blue-Green algal metabolites are concentrated in their biomass. For existence in nature, Blue-Green algae (BGA) secrete and contain various organic substances like proteins, fatty acids, vitamins, pigments, primary and secondary metabolites, and these compounds are explored for potential biological activities such as antibacterial, antifungal, antiviral (including the anti-SARS-CoV-2 virus that causes COVID-19), anticancer, antioxidant, antidiabetic, protease inhibitory activity, anti-inflammatory activity, etc. Due to their diverse application, pharmaceutical companies have shown commercial interest in the Blue-green algal group for the discovery and development of novel molecules to combat deadly diseases for the benefit of society and mankind. The current review paper highlights and discusses the diverse pharmaceutical potential of laboratory-grown cultures of BGA along with comprehensive and current knowledge on bioactive compounds discovered by researchers globally.

* Corresponding author
E-mail: atopath1@amity.edu (Ashutosh Tripathi); akchauhan@amity.edu (Abhishek Chauhan)

All the articles published by Journal of Experimental Biology and Agricultural Sciences are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License Based on a work at www.jebas.org.
1 Introduction

In the extremely competitive environment of current pharmaceutical research and development of new molecules, natural products offer a unique element of molecular diversity and biological functionality, which is essential for drug discovery (Bernardini et al., 2018; Chatterjee et al., 2019; Atanasov et al., 2021). The study of secondary metabolites that organisms such as microbes including BGA and plants have evolved, largely for their survival, has historically proved of immense benefit in drug discovery and development (Petersen et al., 2020). They are providing a rich source of structurally novel bioactive molecules such as lipopeptides, amino acids, fatty acids, etc., many of which have become life-saving drugs (Singh et al., 2021a). In recent decades, pharmaceutical inventions are focused on natural sources (microbial sources such as bacterial, fungi, algal including Blue-green algae) which can deal with recent diseases. Medicinal chemistry is the backbone of lead generation in early drug invention where small molecule hits from high throughput screen (HTS), which leads to limited optimization and identification of lead compounds (Jimenez-Lopez et al., 2021). Despite these efforts, some new chemical entities have reached the market, and researchers throughout the world now are giving more attention to exploring these groups of microorganisms (including microbes from extreme environments i.e., Arctic, Antarctic) for extractions of novel compounds with diverse pharmaceutical applications.

1.1 The need for novel Pharmaceutically important compounds

The less accessibility and high cost of new generation antibiotics necessitate looking for the substances from alternative medicines with claimed antimicrobial activity. Today, most of the diseases caused by pathogens can be cured with the help of available antibiotics, but the discovery of any new antibiotic generally follows up with a course of resistance mechanism building up against it among the target organisms (Dimri et al., 2018). This phenomenon is known as ‘antibiotic resistance is developing among microbial species at an appreciable rate, is a formidable complication of prudent and overuse of available antibiotics, and is imposing a serious health threat to human welfare. World Health Organization (WHO) in February 2017 published a report of antimicrobial-resistant bacteria for which new pharmaceutical compounds are urgently needed (WHO, 2017). Keeping in view the urgent requirement, the current review highlights various important aspects about the pharmaceutical potential of laboratory-grown cultures of BGA.

1.2 Blue-Green Algae

Blue-green algae are a group of extraordinary, diverse, gram-negative, oxygenic, photosynthetic prokaryotic, microscopic oldest organisms that originated 3.5 billion years ago (Kaushik et al., 2009). Blue-green algae are found all over the world, shows remarkable ecological diversity of habitats such as Freshwater (Khatoon et al., 2018; Chittapun et al., 2020), Terrestrial (Radzi et al., 2019; Riba et al., 2020), Marine (Basu et al., 2019; Uma et al., 2020), Hot spring (Tang et al., 2018; Cheng et al., 2020), etc. These BGA are also widely distributed in the polar region such as the Arctic, Antarctic, Southern Ocean, and Himalayas (Singh & Elster, 2007; Rego et al., 2019; Zaki et al., 2020). It has been estimated that about 2000 strains of freshwater and marine BGA are distributed all over the world. The capability to grow in adverse conditions and their autotrophic nature makes them an eligible candidate to grow in low nutrient-deficient lakes, ponds, and oceans which pose a serious threat to water and result in eutrophication. This may cause unpleasant tastes and odors of water through the secretion of volatile compounds. Random screening of blue-green algae will continue to play an important role in the drug discovery process for the foreseeable future. Several studies have been conducted for the isolation and identification of Blue-Green Algae from water, soil, sediments, algal mats, etc. (Figure 1-8) using advanced morphological, physiological, and molecular characterization techniques (Bellinger &Sigee, 2015; Hokmollahi et al., 2016; Radkova et al., 2020). These BGA have successfully grown on a laboratory scale using selective media i.e. BG-11, BG-13, Chu 10 (Chu, 1942; Rippka et al., 1979; Kaushik et al., 2010), Allen and Arnon Medium (Allen & Arnon, 1955), Fogg’s Medium (Fogg’s, 1965), Modified Bristol’s Medium (Bold, 1949) and Pringsheim’s Medium (Pringsheim, 1946). Blue-green algae do not require carbon or energy sources in their growth medium. Thus, they require only a basic inorganic medium, which has several logical advantages when performing the mass culture and purification of active compounds. Flask cultivation and mass cultivation for instance open pond system, hybrid system, closed photobioreactors are very well-known culturing methods used for generating biomass maintaining proper light, temperature, water, CO₂ supply, pH, nutrient supply, and proper mixing (Kaiwanarporn et al., 2012; Troschel et al., 2017; Al-Saman et al., 2020; Jo et al., 2020). Lyophilization (freeze-drying), air drying, and sun-drying are some known popular techniques to convert biomass into powder (Smetana et al., 2017). Aqueous extraction i.e. cold and hot water extraction, organic extraction i.e. polar solvent extraction, semi-polar solvent extraction, non-polar solvent extraction, mix solvents extraction and sequential extractions, soxhlet extraction have been used extensively to isolate medicinal value active ingredients (Fatima et al., 2017; Vanalveni et al., 2018; Yücer et al., 2018; Saurav et al., 2019). Generally, all blue-green algae vegetative cells contain carboxysomes, pseudocrystalline aggregates of the key enzymes of CO₂ fixation via the reductive pentose phosphate pathway and glycogen is a general carbohydrate reserve material of cyanobacteria. Other cellular inclusions include Poly-β-hydroxybutyrate (PHB) granules, cyanophycin granules, polyphosphate granules, carboxysomes or polyhedral bodies, and gas...
vesicles (Stanier, 1988). They show notable ecological diversity. Because of extensive eutrophication of lakes, ponds and some parts of oceans BGA often forms blooms, which lead to water hygienic problems (Chorus et al., 2000; Duy et al., 2000). They may cause unpleasant tastes and odors through the excretion of volatile compounds (Jones & Korth, 1995; Liu et al., 2006).

Figure 1 Laboratory Grown Culture of BGA (Medium: BG-11): A. *Calothrix* sp., B. *Spirulina* sp. C. *Oscillatoria* sp.

Figure 2 Microscopic images of *Anabaena* species (Chauhan & Jindal, 2020)

Figure 3 Microscopic images of *Nostoc* species (Chauhan & Jindal, 2020)

Figure 4 Microscopic images of *Calothrix* species (Chauhan & Jindal, 2020)
Pharmaceutical potential of laboratory grown cultures of blue-green algae: a comprehensive review and future possibilities

Figure 5 Microscopic images of Oscillatoria species (Chauhan & Jindal, 2020)

Figure 6 Microscopic images of spirulina species (Chauhan & Jindal, 2020)

Figure 7 Scanning Electron Micrograph (SEM) image of Anabaena sp. (A) and Nostoc sp. (B) as per Kaushik & Chauhan (2008a)

Figure 8 Scanning Electron Micrograph (SEM) image of Spirulina platensis (Kaushik & Chauhan, 2008b)
2 Pharmaceutical Potential of BGA

Blue-green algae are the rich source of structurally novel and biologically active metabolites with diverse antibacterial, antifungal, antiviral (including the anti-SARS-CoV-2 virus that causes COVID-19), anticancer, antioxidant, anti-inflammatory activity, anti-infectious disease activity, immunomodulatory, larvicide, and protease inhibitory activity, etc. (Figure 9) (Nainangu et al., 2020; Jafari et al., 2021). The first time before 1500 BC, medicinal and nutritional properties have been investigated for Nostoc algal species to treat gout, fistula, and cancer (Cardellina et al., 1979a; Shishido et al., 2020).

These photosynthetic microorganisms can yield proteins, carbohydrates, and lipids as a result of photosynthesis thus referred to as important biological resources having a wide range of biotechnological applications in the modern world due to their ability to grow rapidly even in harsh environmental conditions (Padmini et al., 2021). A search of these organisms for medicinal purposes has revealed important chemical prototypes for the finding of new agents, stimulating the use of refined physical techniques and new syntheses of molecules with the pharmaceutical application for human welfare. Phytochemical’s constituents described from extracts of Blue-Green algae have been described by researchers (Figure 10) and are very well documented (Vasudevan et al., 2020; Nainangu et al., 2020; Gabr et al., 2020; Vasudevan et al., 2020).

2.1 Pharmaceutically important compounds isolated from BGA

Secondary metabolites refer to those compounds that are not used by the organisms for their primary metabolisms. Secondary metabolites influence other organisms in the vicinity and are thought to be of phylogenetic importance (Carpine & Sieber, 2021). Secondary metabolites include several types of compounds that may act as hormones, antibiotics, allelochemicals, toxins, and biotoxins that are found in surface supplies of fresh water (Carmichael, 1992). The ability of such compounds to kill bacteria and fungi have been well documented (Bonjouklian et al., 1988).

The properties of secondary metabolites in nature are not completely understood (Metting & Pyne, 1986; Inderjit & Dakshini, 1994; Vasudevan et al., 2020). The blue-green algae bear the characteristics to secrete vitamins, amino acids, fatty acids, carbohydrates, and various primary and secondary metabolites like amines, histamines, histidine, tannins, terpenoids, bromophenol, and polysaccharides (Figure 11). Few of these compounds are proven to be biologically active (Metting & Pyne, 1986; Padmini et al., 2021). The recent examples are cyanovirin-N secreted by Nostoc ellipposporum and anti-HIV glycolipids secreted by Isochrysis and bromophenol are secreted by Calothrix sp. (Jaspars & Lawton 1998; Safari et al., 2020).

Figure 9 Pharmaceutical Potential of Blue-Green Algae

Figure 10 Major Phytochemicals constituents described from extracts of Blue-Green algae
Pharmaceutical potential of laboratory grown cultures of blue-green algae: a comprehensive review and future possibilities

2.1.1 Antibacterial Potential of BGA

BGA are known for the secretions of antibacterial compounds with potential antibacterial activity against both Gram-positive and Gram-negative bacteria. Several strains such as Anabaena, Lyngbya, Calothrix, Spirulina, Nostoc, Hapalosiphon, Phormidium, and Oscillatoria have been identified by researchers from different habitats which can produce a wide variety of antibacterial molecules having therapeutic potentials (Chauhan et al., 2022). These organisms are even being altered genetically using biotechnological interventions for the production of various active compounds having antibacterial activity such as Bacteriocin Ambigol A, Parsiguine, Hapalindole, Hormothamnin A. Bacillus subtilis, Staphylococcus aureus, Streptococcus sanguinis, Pseudomonas aeruginosa, Escherichia coli, L. monocytogenes, Salmonella typhimurium, Enterobacter aerogenes, Klebsiella pneumonia, Methicillin-resistant B. anthracis are the examples of some gram-positive and Gram-negative bacteria which have studied for the inhibitory action of BGA (Luesch et al., 2001; Muller et al., 2006; Mo et al., 2009; Sturdy et al., 2010). The first partly identified antimicrobial compound isolated from algae were obtained from unicellular green algae particularly, Chlorella which contained a substance termed as ‘chlorellin’ that exhibited inhibitory activity against both Gram-positive and Gram-negative bacteria, including Staphylococcus aureus, Streptococcus pyogenes, Bacillus subtilis, and Pseudomonas aeruginosa (Pratt et al., 1944). Chlorellin is composed of peroxides of unsaturated fatty acids (Spoehr & Milner, 1949). Kaushik & Chauhan (2008a) had reported the antibacterial activity of several species of cyanobacteria such as Anabaena, Lyngbya, Calothrix, Spirulina, Nostoc, Hapalosiphon, Phormidium, and Oscillatoria, etc. against both Gram-positive (Staphylococcus aureus, Bacillus subtilis, Bacillus cereus, etc.) and Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella typhi, etc.). In a similar study, various species of Anabaena were evaluated for their antimicrobial activity and active antibacterial extracts were further screened for the presence of various chemical constituents through HPTLC techniques (Kaushik et al., 2009; Chauhan et al., 2010). Extracts of Nostoc commune and Lyngbya majuscula were studied for potent antimicrobial activity against clinically significant microorganisms (Kaushik & Chauhan, 2008a; Kaushik & Chauhan 2008b; Kaushik et al., 2009; Verma et al., 2016). HPTLC analysis were also performed to identify novel pharmaceutical compounds responsible for the activity. In a recent study, El-Sheekh et al. (2021) have evaluated the antibacterial activity of Oscillatoria sp. and Spirulina mediated silver and gold nanoparticles. Two new antibacterial molecules namely Arachidonoyl dopamine and fluocinolone recently discovered from methanolic extracts of Arthrospira platensis, a BGA isolated from a hypersaline lake in Rajasthan, India (Singh et al., 2021b). In another study, Antibacterial efficacy extracts of Oxynema thaihianum have been assessed against multi-drug-resistant bacteria such as E. coli and K. pneumoniae (Padmini et al., 2021). Antibacterial compounds discovered from various species of BGA have been listed in Table 1 and Figure 12.
### Table 1: Antibacterial compounds reported from BGA

| BGA Sps.                  | Antibacterial Compounds                                                                 | Detail of Chemical compounds                                                                 | References       |
|---------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------|
| *Scytonema pseudo hofmanni* | Scyphycins C                                                                           | IUPAC Name: N-[(E,3S,4R,5R,9S,10S,11S)-10-hydroxy-11-[(1S,9S,15S,25R,28S,31S,40S,43R,46S,48S,56S)-28,31,34,37,39,42,45,48,51,53,55,57-dodecahydroxyphenyl]-12-(hydroxymethyl)-17,48-bis(3-methylbut-2-enyl)-43-(2-methylpropyl)-2,8,11,14,17,23,30,33,36,39,42,45-undeca-1,3,7,10,13,24,26,29,32,35,38,41,44,47,50,53,56,59,62-tridecazaoctacyclo[44.10.0.03,7.04,9.014,19.017,25.048,56.049,54]hexa-pentaconta-18,20,22,49,51,53-hexaen-34-yl]acetic acid | Ishibashi et al., 1986 |
| *Scytonema ocellatum, Tolypothrix conglutinate* | Tolypothrix ambigua                                                                   | IUPAC Name: N-[(E,3S,4R,5R,9S,10S,11S)-10-hydroxy-11-[(1S,9S,15S,25R,28S,31S,40S,43R,46S,48S,56S)-28,31,34,37,39,42,45,48,51,53,55,57-dodecahydroxyphenyl]-12-(hydroxymethyl)-17,48-bis(3-methylbut-2-enyl)-43-(2-methylpropyl)-2,8,11,14,17,23,30,33,36,39,42,45-undeca-1,3,7,10,13,24,26,29,32,35,38,41,44,47,50,53,56,59,62-tridecazaoctacyclo[44.10.0.03,7.04,9.014,19.017,25.048,56.049,54]hexa-pentaconta-18,20,22,49,51,53-hexaen-34-yl]acetic acid | Prinsep et al., 1992 |
| *Fuscherella ambigua*      | Ambigol A                                                                              | IUPAC Name: 3,5-dichloro-2,3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol      | Falch et al., 1995 |
| *Nostoc muscorum*          | Muscoride A                                                                            | IUPAC Name: 3,5-dichloro-2,3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol      | Ishida et al., 1997 |
| *Fuscherella ambigua*      | Tjipanazole D                                                                          | Compound CID: 10087661                                                                    | Nagata et al., 1995 |
| *Microcystis aeruginosa*   | Kawaguchipeptin A                                                                     | IUPAC Name: 3,5-dichloro-2,3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol      | Falch et al., 1995 |
| *Nostoc spongiforme var. tenue* | Tenuecyclamide A                                                                   | IUPAC Name: 3,5-dichloro-2,3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol      | Falch et al., 1995 |
| *Nostoc commune*           | 1,8-dihydroxy-4-methyl anthraquinone                                                   | IUPAC Name: 3,5-dichloro-2,3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol      | Falch et al., 1995 |
| *Calothrix sp.*            | Calothrixin A                                                                          | IUPAC Name: 3,5-dichloro-2,3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol      | Falch et al., 1995 |
### Pharmaceutical potential of laboratory grown cultures of blue-green algae: a comprehensive review and future possibilities

| BGA Sps. | Antibacterial Compounds | Detail of Chemical compounds | References |
|----------|-------------------------|------------------------------|------------|
| **Nostoc commune** | Connastin A | MF: C_{21}H_{48}O_{14}; MW: 981.5g/mol | Jaki et al., 2000 |
| | Nostocine A | MF: C_{18}H_{28}O_{8}; MW: 342.5g/mol | Ploutno & Carmeli, 2000 |
| | Nostoc spongioforme | a-dimorphelic acid | Hirata et al., 2003 |
| **Oscillatoria redekei** | | MF: C_{21}H_{26}O_{13}; MW: 515.13g/mol | Mundt et al., 2003 |
| **Scytonema hofmanni PCC 7110** | Scyptolin A | MF: C_{6}H_{10}Cl_{2}O_{2}; MW: 147.27g/mol | MacMillan & Molinski, 2005; Matern et al., 2001 |
| **Lyngbya sp.** | Pahayokolide A | MF: C_{10}H_{12}O_{8}; MW: 174.2g/mol | Berry et al., 2004 |
| **Microcoleus lacustris** | Abietane | MF: C_{30}H_{50}O_{10}; MW: 455.7g/mol | Thajuddin & Subramanian, 2005 |
| **Fischerella sp.** | Hapalindole T | MF: C_{31}H_{32}Cl_{2}O_{5}; MW: 536.9g/mol | Asthana et al., 2009 |
| **Fischerella ambigua** | Ambigol B | MF: C_{28}H_{44}ClO_{3}; MW: 485g/mol | Raveh & Carmeli, 2007 |
| **Nostoc sp.** | Carbamidocyclophane A | MF: C_{33}H_{48}Cl_{4}N_{2}O_{8}; MW: 808.6g/mol | Bui et al., 2007 |
| | Nostocaroline Hydroiodide; Nostacaroline Iodide | MF: C_{32}H_{48}ClN_{2}; MW: 344.58g/mol | Becher et al., 2007 |
| **Fischerella ambigua** | Ambiguine A | MF: C_{23}H_{38}C_{3}N_{2}; MW: 407g/mol | Mo et al., 2009 |

Journal of Experimental Biology and Agricultural Sciences
http://www.jebas.org
| BGA Sps.         | Antibacterial Compounds | Detail of Chemical compounds                                                                 | References       |
|------------------|-------------------------|-----------------------------------------------------------------------------------------------|------------------|
| *Fischerella*    | Ambiguine A             | MF: C_{26}H_{31}ClN_{2}  
MW: 407g/mol  
IUPAC Name: (2S,3R,4R,5R,7S)-5-chloro-4-ethenyl-3-isocyano-4,8,8-trimethyl-15-(2-methylbut-3-en-2-yl)-14-azatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),9(16),10,12-tetraene |
| *ambigua*        | isonitrile              |                                                                                               | Mo et al., 2009  |
| *Leptolyngbya*   | Crossbyanol A           | MF: C_{32}H_{15}Br_{7}O_{6}  
MW: 1030.8g/mol  
IUPAC Name: 3-bromo-4-[(2-bromo-4-(3-bromo-4-hydroxyphenoxy)phenoxy]-6-(2,4-dibromophenoxy)phenoxy]-2-(2,4-dibromophenoxy)phenol |
| *crosbyana*      |                         |                                                                                               | Choi et al., 2010|
| *Nostoc* sp.     | 9-Ethyliminomethyl-12-(morpholin-4-ylmethoxy) 5, 8, 13, 16-tetraaza-hexacene-2, 3 dicarboxylic acid (EMTAHDC) |                                                                                               | Niveshika et al., 2016 |

**Chemical Structures:**

- Scytophycins C
- Tolytoxin
- Tolyporphin J
- Ambigol A
- Muscoride A
- Tjipanazole D
- Kawaguchipeptin A
- Tenuecyclamide A
- 1,8-dihydroxy-4-methyl anthraquinone
- Calothrixin A
- Comnastin A
- Nostocycline A
- Nostocine A
- a-dimorphecolic acid
- Scyptolin A
- Pahayokolide A
2.1.2 Antimycobacterial potential of BGA

BGA extracts and compounds have been tested against various species of Mycobacteria. Rao et al. (2007) reported the antimycobacterial activity of different spp. of BGA viz., Hapalosiphon sp., Anabaena sp. Lyngbya sp., Westeillopsis prolifica, Spirulina sp. Anabaena variabiles, Anabaena cylindrica, Oscillatoria sp. and Scytonema sp. against Mycobacterium tuberculosis ATCC 27294, M. tuberculosis MDR, M. avium, M. intracellulare, and M. aurum. Other BGA species which exhibit antimycobacterial potential are Tychonema sp., Fischerella ambigua are Lyngbyama juscule (Muller et al., 2006; Mo et al., 2009; Sturdy et al., 2010; Luesch et al., 2001). Antimycobacterial compounds produced by these BGA strains are summarized in Table 2.

2.1.3 Antifungal potential of BGA

Antifungal properties of BGA strains have been documented globally. Fungal and yeast strains such as Candida fiedrickii, Fusarium oxysporum, Aspergillus fumigatus, Alternaria alternate, A. niger, A. parasiticus, A. flavus, A. westerdijkia, A. ochraceus ITAL 14, A. carbonarius ITAL 204, A. steynnii IBT LKN 23096, Penicillium verrucosum BFE 500, F. verticillioides ITEM 10027, F. proliferatum MPVP 328 have been tested with BGA extracts and compounds (Marrez & Sultan, 2016; Vanlalveni et al., 2018; Saurav et al., 2019). Antifungal compounds reported from BGA strains have been listed in Table 3 and Figure 13.

Blue-green algae produce large amounts of antioxidants to protect themselves from harmful stress conditions so that the cells can be protected from the effect of the reactive oxygen species (ROS) produced during stress. Hydrogen peroxide and oxygen free radicals are the two harmful reactive oxygen species formed in the cells during oxidative stress and can damage the cells (Vasudevan et al., 2020). Antioxidant properties of various extracts have been evaluated using different assay methods such as DPPH radical-scavenging Assay, ABTS+ (2, 2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid); Nitric oxide radical scavenging Assay; Total Antioxidant capacity determination kit, and β-carotene bleaching assay (Table 5). BGA produces several antioxidants that can scavenge these free radicals. These antioxidants have been explored as a novel source of dietary supplements because the cyanobacteria are rich in phenolics, vitamins, and carotenoids, the most common being carotenoids, which can be used for alleviating oxidative stress and limiting health problems (Nainangu et al., 2020; Gabr et al., 2020). ROS are also formed in animals and humans during oxidative stress and cause damage to the biomolecules such as lipids, proteins, and DNA. Oxidative stress is associated with several diseases such as cancer, neurodegeneration, retinopathy, aging, and other diseases. Algae produce several substances that have antioxidant effects, and these substances can be used as dietary supplements by humans (Guerreiro et al., 2020; Safari et al., 2020; Li et al., 2020). Antioxidant compounds recently purified from Blue-Green Algae are summarized in Table 4.
Table 2 Antimycobacterial compounds reported from BGA

| BGA Spp. | Antimycobacterial Compounds | Chemical Structure | References |
|----------|-----------------------------|-------------------|------------|
| Typhonema sp. | **Brunsvicamide A**<br>MF: C₄₅H₆₄N₈O₈<br>MW: 845g/mol | ![Chemical Structure](image1) | Muller et al., 2006 |
| Typhonema sp. | **Brunsvicamide B**<br>MF: C₄₆H₆₆N₈O₈<br>MW: 859.1g/mol | ![Chemical Structure](image2) | Muller et al., 2006 |
| Fischerella ambigua | **Eucapsitrione**<br>MF: C₁₇H₁₀O₆<br>MW: 358.3g/mol | ![Chemical Structure](image3) | Sturdy et al., 2010 |
| Lyngbya majuscula | **Pitipeptolide A**<br>MF: C₄₄H₆₅N₅O₉<br>MW: 808g/mol | ![Chemical Structure](image4) | Luensch et al., 2001 |
| Lyngbya majuscula | **Pitipeptolides C**<br>MF: C₄₄H₆₉N₅O₉<br>MW: 812g/mol | ![Chemical Structure](image5) | Mo et al., 2009 |
### Table 3 Antifungal compounds reported from BGA

| BGA Spp.               | Antifungal Compounds     | Detail of Chemical compounds                                                                 | References                  |
|------------------------|--------------------------|------------------------------------------------------------------------------------------------|----------------------------|
| Hyella caespitosa      | Carazostatin            | MF: C_{21}H_{28}N_{10}O_{8}MW: 736.47g/molIUPAC Name: 1-heptyl-2-methyl-9H-carbazol-3-ol       | Cardellina et al., 1979a    |
| Scytonea hofmanni      | Cyanobacterin            | MF: C_{15}H_{12}ClO_{3}MW: 285.79g/molIUPAC Name: (5Z)-3-[(7-chloro-1,3-benzodioxol-5-yl)methyl]-4-hydroxy-5-[(4-methoxyphenyl)methyldiene]-4-propan-2-ylxolan-2-one | Mason et al., 1982          |
| Tolypothrix tenuis     | Toyocamycin              | MF: C_{12}H_{12}N_{2}O_{4}MW: 226.25g/molIUPAC Name: 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)xoxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile | Moore, 1982                 |
| Tolypothrix tenuis     | Tubercidin               | MF: C_{18}H_{18}ClO_{4}MW: 680.27g/molIUPAC Name: (2R,3R,4S,5R)-2-[(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)xozone-3,4-diol | Moore et al., 1987          |
| Hapalosiphon fontinalis| Anhydrohaloxindole A;   | MF: C_{37}H_{42}ClN_{3}O_{4}MW: 695.46g/molIUPAC Name: (3R,4R,5R,7R)-5-chloro-4-ethenyl-3-isocyno-4,8,8-trimethyl-14-azatetracyclo[7,6.1.0^{2,7}.13,16]hexadeca-1,9(16),10,12-tetraen-15-one | Moore et al., 1987          |
| Hapalosiphon fontinalis| Anhydrohaloxindole A    | MF: C_{37}H_{42}ClN_{3}O_{4}MW: 695.46g/molIUPAC Name: (3R,4R,5R,7R)-5-chloro-4-ethenyl-3-isocyno-4,8,8-trimethyl-14-azatetracyclo[7,6.1.0^{2,7}.13,16]hexadeca-1,9(16),10,12-tetraen-15-one | Moore et al., 1987          |
| Nostoc sp.             | Nostocyclamide           | MF: C_{25}H_{22}N_{10}O_{4}MW: 567.51g/molIUPAC Name: (4S,18R)-4,7-dimethyl-18-propan-2-yl-6-oxa-13,20-dithia-3,10,17,22,23,24-hexazatetracyclo[17,2.1,5,8,11,15]tetracosa-1(21),5(24),7,12,13,14,19(22)-hexaene-2,9,16-trione | Moore et al., 1988          |
| Hormothamnion enteromorphoides | Hormothamn A       | MF: C_{40}H_{40}N_{11}O_{4}MW: 867.70g/molIUPAC Name: (3Z)-28-benzyl-19,22-dibutan-2-yl)-3-ethylidene-36-hydroxy-6,31-bis-(2-hydroxyethyl)-16,25-bis-(2-methylpropyl)-10-pentyl-1,4,7,11,14,17,20,23,26,29,32,undeceazabicyclo[32.3.0]heptatriacontane-2,5,8,12,15,18,21,24,27,30,33,undecone | Gerwick et al., 1989         |
| Calothrix fusca        | Calophycin               | MF: C_{36}H_{36}N_{10}O_{4}MW: 719.68g/molIUPAC Name: (3R)-2-[(4-dihydroxyphenyl)methyl]-1,3,4,9-tetrahydropyrrol[3,4-b]indole-3-carboxylic acid | Moon et al., 1992           |
| Dichothrix baueriana   | Bauerine B               | MF: C_{24}H_{23}ClN_{3}MW: 408.15g/molIUPAC Name: 7,8-dichloro-9-methylpyridol[3,4-b]indole | Larsen et al., 1994         |
| Nostoc sp. ATCC 53789) | Cryptophycin 1           | MF: C_{25}H_{25}ClN_{3}O_{3}MW: 655.24g/molIUPAC Name: (3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-(1S)-[(2R,3R)-3-phenoxiran-2-yl]etyl]-1,4-dioxo-8,11-diazyacyclohexadec-13-ene-2,5,9,12-tetraone | Trinumturu et al., 1994 |
| Hapalosiphon welwitschi, Westiella intricate | Welwitindolinone A isonitrile | MF: C_{23}H_{23}ClN_{3}O_{3}MW: 655.24g/molIUPAC Name: (3S,3'S,4'R,6'R)-4'-chloro-3'-ethenyl-2'-isocyno-3',7',7'-trimethylspiro[1H-indole-3,8'-bicycle[4,2,0]oct-1-ene]-2-one | Stratmann et al., 1994 |
| BGA Spp.          | Antifungal Compounds | Detail of Chemical compounds                                                                 | References                  |
|-------------------|----------------------|------------------------------------------------------------------------------------------------|-----------------------------|
| *Nostoc commune* | Nostofungidicine     | IUPAC Name: 2-[16-(2-amino-1-hydroxy-2-oxoethyl)-27-hydroxy-19-[hydroxy-(4-hydroxyphenyl)methyl]-3,22-bis(hydroxymethyl)-10-(3-hydroxypropenyl)-2,5,8,12,15,18,21,24-octaoxy-1,4,7,11,14,17,20,23-octazabicyclo[23.3.0][octacosan-13-y]-2-hydroxyacetamide | Kajiyama et al., 1998       |
| *Fischerella muscicola* | Fischrellin B           | MF: C_{22}H_{39}NO             IUPAC Name: (3R,5S)-3-methyl-5-[(E)-pentadec-5-en-7,9-diynyl]pyrrolidin-2-one | Srivastava et al., 1999       |
| *Lyngbya majuscula* | Tanikole               | MF: C_{7}H_{16}O_{3}            IUPAC Name: (6R)-6-(hydroxymethyl)-6-undecyloxyan-2-one | Singh et al., 1999           |
| *Scytonema pseudo hofmannii* | Scytophycin A             | MF: C_{26}H_{42}NO_{12}           IUPAC Name: N-[(E,3R,4R,5S,9S,10S,11S)-6,10-dihydroxy-11-[(18S,8S,7R,8S,9R,12E,14E,17S,19R)-17-hydroxy-3,5,7-trimethoxy-8,14-dimethyl-11-oxospiro[10,23]-dioxabicyclo[17.3.1]tricosa-12,14,20-triene-4,2'-oxirane]-9-yl]-4-methoxy-3,5,9-trimethyldec-1-enyl]-N-methylformamide | Matern et al., 2001          |
| *Tolyphothrix byssodea* | Tolybyssidin A          | MF: C_{27}H_{41}N_{10}O_{8}              IUPAC Name: 1-[13S,6S,9S,12S,15S,18Z,21S,24S,27S,30S,33S,36S,39S]-21-benzyl-24,27-bis[2S]-butan-2-yl]-36-[3-(diaminomethylamino)propyl]-18-ethyldiene-9,30-bis[(1R)-1-hydroxyethyl]-33-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-3,6,15-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31,34,37-tridecazyclononatriacont-12-yl]ethyl acetate | Jaki et al., 2001           |
| *Tolyphothrix byssodea* | Tolybyssidin B          | MF: C_{27}H_{41}N_{10}O_{8}              IUPAC Name: 2-[3S,6S,9S,12S,15S,18Z,21S,24S,27S,30S,33S,36S,39S]-32-benzyl-17-[(2S)-butan-2-yl]-38-ethylidene-14,20-bis[(1R)-1-hydroxyethyl]-5-[(4-hydroxyphenyl)methyl]-8-(2-methylsulfanyylethyl)-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaoxo-11,23,26,29,35-penta(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31,34,37-tridecazyclononatriacont-2-yl]propylguanidine | Jaki et al., 2001           |
| *Lyngbya confervoides* | Lobocyclamine B              | MF: C_{57}H_{66}N_{20}O_{10}            IUPAC Name: 3-[[(3S,6S,9S,12R,15R,18S,21R,24S,28R,31S,34R,37S,39R)-9-[(2S)-butan-2-yl]-6-[(1R)-1,2-dihydroxyethyl]-28-heptyl-39-hydroxy-3,31-bis[(1R)-1-hydroxyethyl]-15,21-bis[(1S)-1-hydroxy-2-methylpropyl]-10,18-dimethyl-34-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,30,33,36-dodecaoxo-24-propan-2-yl]-1,4,7,10,13,16,19,22,25,28,31,34,37-tridecazyllonatriacont-12-y]propanamide | MacMillan et al., 2002       |
| *Nostoc commune* | Nostodione A             | MF: C_{4}H_{10}NO_{3}             IUPAC Name: (3E)-3-[(4-hydroxyphenyl)methylidene]-4H-cyclopenta(b)indole-1,2-dione | Bhadury & Wright, 2004       |
| *Hassallia sp.*   | Hassallidin A           | MF: C_{2}H_{2}N_{2}O_{4}            IUPAC Name: N-[2(S,3R)-1-[[3S,6S,12S,15Z,18S,21S,24S,25R]-3,12-bis[(3-amino-3-oxo)propoxy]-15-ethylidene-21-[(1R)-1-hydroxyethyl]-18-[(4-hydroxyphenyl)methyl]-7,25-dimethyl-2,5,8,11,14,17,20,23-octaoxy-6-[(1R)-1-[2S,3S,4S,5S,6R]-3,4,5-trihydroxy-6-hydroxymethyl]oxan-2-yl][oxetyl]-1-oxa-4,7,10,13,16,19,22-heptazacylclooctacos-24-yl][amino]-3-hydroxy-1-oxobutan-2-yl]-2,3-dihydroxytetradecanamide | Neuhof et al., 2005           |
Pharmaceutical potential of laboratory grown cultures of blue-green algae: a comprehensive review and future possibilities

| BGA Spp.                     | Antifungal Compounds          | Detail of Chemical compounds                                                                 | References                     |
|------------------------------|-------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------|
| *Fischerella ambigua*        | 2,4-dichlorobenzoic acid      | MF: C₇H₅Cl₂O₂  
MW: 191.01g/mol  
IUPAC Name: 2,4-dichlorobenzoic acid | Wright et al., 2005 |
| *Geitlerinema sp.*           | Swinholide A                  | Name: (1R,3S,5E,7E,11S,12S,13R,15S,16S,17S,19S,23R,25R,27Z,29E,33S,34S,35R,37S,38S,39S,41S)-3,13,15,25,37-hexahydroxy-11-[(2S,3S,4R)-3-hydroxy-6-[(2S,4R,6S)-4-methoxy-6-methylxan-2-yl]-4-methylhexan-2-yl]-33-[(2S,3S,4S)-3-hydroxy-6-[(2S,4R,6S)-4-methoxy-6-methylxan-2-yl]-4-methylhexan-2-yl]-17,39-dimethoxy-6,12,16,28,34,38-hexamethyl-10,32,45,46-tetraoxatricyclo[39.3.1.19,23]hexatetraconta-5,7,21,27,29,43-hexaene-9,31-dione | Andrianasolo et al., 2005 |
| *Fischerella ambigua*        | Tjipanazole B                 | MF: C₁₉H₁₈Cl₂N₂O₄  
MW: 457.3g/mol  
IUPAC Name: (2R,3R,4S,5R)-2-(3,8-dichloro-11H-indolo[2,3-a]carbazol-12-yl)oxane-3,4,5-triol | Wright et al., 2005 |
| *Nadularia harveyana*        | Norharmane                    | MF: C₁₁H₈N₂  
MW: 168.19g/mol  
IUPAC Name: 9H-pyrido[3,4-b]indole | Volk & Furkert, 2006 |
| *Synechocystis sp.*          | AK-3                          | MF: C₁₉H₂₁N₂O₅S  
MW: 228.32g/mol  
IUPAC Name: 2-(dimethylamino)-N(5-propyl-1,3,4-thiadiazol-2-yl)acetamide | Yoon et al., 2006 |
| *Lyngbya majuscula*          | Hectorchlorin                 | MF: C₂₇H₃₄Cl₂N₂O₉S₂  
MW: 665.6g/mol  
IUPAC Name: [(5S,12S,13S,16S)-12-(4,4-dichloropentyl)-16-(2-hydroxypropan-2-yl)-4,4,13-trimethyl-2,10,14-triexo-3,11,15-trioxa-7,18-dithia-20,21-diazatricyclo[15.2.1.16,9]henicosa-1(19),6(21),8,17(20)-tetraen-5-yl] acetate | Gademann & Portmann, 2008 |
| *Calothrix elenkinii*        | Benzoic Acid                  | MF: C₇H₆O₂  
MW: 122.12g/mol  
IUPAC Name: benzoic acid | Natarajan et al., 2012 |

![Image of chemical structures](http://www.jebas.org)
Figure 13 Chemical structures of the active ingredients isolated from various BGA and having antifungal properties.
### Table 4 Antioxidants compounds recently purified from Blue-Green Algae

| Antioxidants compounds                                      | Source                        | References             |
|-------------------------------------------------------------|-------------------------------|------------------------|
| Pyrogallol, E-Vanillic, Hesperidin                          | *Spirulina platensis*         | Gabr et al., 2020      |
| Benzeneacetanomide and Norvaline, n-propargyloxycarbonyl    | *Microcystis aeruginosa*      | Vasudevan et al., 2020 |
| BHA, Beta tocopherol, Phytosterols                          | *Spirulina maxima*            | Gamal et al., 2020     |
| Caffeic acid, syringic acid, ferulic acid, p-coumaric acid, | *Spirulina platensis*         | Bellahcen et al., 2020 |
| kaempferol, quercetin and apigenin γ-linolenic acid, α-linolenic acid | *Oscillatoria sp. SSCM01*     | Nainangu et al., 2020  |

### Table 5 Types of BGA Extracts, Assay methods and their antioxidant potential

| Blue-Green Algae         | Type of Extract                        | Assay methods                      | Maximum Activity | References                         |
|--------------------------|----------------------------------------|------------------------------------|------------------|------------------------------------|
| *Spirulina platensis*    | Ethanolic and aqueous extract           | DPPH radical-scavenging Assay      | 96.33%           | Gabr et al., 2020                  |
| *Microcystis aeruginosa* | Methanol Extract                        | Scavenging ability on 1, 1-diphenyl-2-picyrylhydrazyl radicals (DPPH) Hydroxyl radical scavenging assay | 54%              | Vasudevan et al., 2020             |
| *Spirulina maxima*       | -                                      | DPPH radical-scavenging Assay      | 25.73%           | Gamal et al., 2020                 |
| *Spirulina platensis*    | Ethanolic, aqueous, and lipidic extracts | DPPH (2, 2'-diphenyl-1-picyrylhydrazyl) ARTS* (2, 2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (IC50 = 449 μg/mL ± 83) (IC50 = 740 μg/mL ± 12) | (IC50 = 449 μg/mL ± 83) (IC50 = 740 μg/mL ± 12) | Bellahcen et al., 2020             |
| *Oscillatoria sp. SSCM01*| MeOH: CHCl₃ fraction                   | DPPH radical scavenging assay      | 48%              | Nainangu et al., 2020              |
| *Spirulina platensis*    | crude extracts                          | DPPH radical scavenging activity   | 45.75%           | Safari et al., 2020                |
| *Oscillatoria acuminate*| Methanolic extract                      | DPPH (2, 2'-diphenyl-1-picyrylhydrazyl) ARTS* (2, 2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) | 6.58 %           | Gheda & Ismail (2020).             |
| *Dolichospermum flos-aquae HSSASE2* | | DPPH radical scavenging assay | (467.7 μg/ml) | Senousy et al., 2020               |
| *Anabaena sp., Stigonaema sp., and Oscillatoria sp.* | Methanol Extract                        | Total Antioxidant capacity determination kit | 0.346 (mM/L); 0.37 (mM/L) | Seddek et al., 2019               |
| *Aphanizomenon gracile (LMECYA 009), Aphanizomenon flos-aquae (LMECYA 088), Nostoc (LMECYA 291), Planktothrix mougeotii (LEGE 06224)* | Methanolic and ethanolic | DPPH scavenging method, β-carotene bleaching assay | 10.7% | Guerreiro et al., 2019            |

---

Journal of Experimental Biology and Agricultural Sciences
http://www.jebas.org
2.1.5 Anti-cancer potential of BGA

BGA extracts and compounds are known to exhibit anticancer properties (Shishido et al., 2020; Gara-Ali et al., 2021). Research by Jaspers & Lawton (1998) has focused on various biologically active compounds from BGA. The curian A, a novel lipid compound isolated from Lyngbya majuscula, is a potent inhibitor of microtubule assembly with very low IC50 values against L1210 leukemia cells and CD-46 Burkitt lymphoma cells, at par with those for colchicines. Cryptophycin 1 and 8, another anticancer compound was first isolated from Nostoc sp. by researchers at Merck. The oral supplement of Spirulina fusiformis is known for regression of subjects with homogenous leukolakia (Mathew et al., 1995). The extracts of Spirulina and Dunaliella inhibited the chemically induced carcinogenesis in model hamster buccal pouches (Schwartz et al., 1988). Studies have also shown that sulphated polysacharide, calcium spirulans appears to inhibit tumor invasion of melanoma cells and basement membrane (Mishima et al., 1998). Aphanizomenon flosaquae extract containing a high concentration of phycocyanin inhibited the in vitro growth of tumour cells, indicating the sensitivity of cell lines to the phycocyanin. A filamentous cyanobacterium Phormidium tenue contains several diacylglycerols that inhibit chemically induce tumors on mice (Tokuda et al., 1996). Similarly, cryprophycin 1 isolated from Nostoc sp. (ATCC 53789) is the most potent suppressor of microtubule dynamics i.e. it blocks all cell cycles in G2/M phase. Curacin A is isolated from Lyngbya majuscula. This compound is found to be a potent inhibitor of microtubule assembly. There is a need for immediate attention for more novel anticancer drugs so that carcinogenic cells are capable of resisting some drugs, like vinca alkaloids and taxanes. These drugs failed to treat cancer in a chemotherapeutic way. Cancer is known to be the major cause of mortality worldwide. Recently some new types of cancer e.g. glioblastoma are increased rapidly. Anticancer compounds reported from BGA are summarized in Table 6 Figure 14.

| BGA Spp.     | Anticancer Compounds | Chemical Structure                                                                 | References               |
|--------------|----------------------|-----------------------------------------------------------------------------------|--------------------------|
| Calothrix sp.| Calothrixin A         | MF: C40H39N5O5; IUPAC Name: 20-oxido-10-aza-20-azoniapentacyclo[11.8.0.3,11.0.4.9.0.14,19]benicos-1(3),3(11),4,6,8,14,16,18,20-nonaene-2,12-dione | Cardellina et al., 1979b |
| Nostoc sp.   | Boromycin             | MF: C49H37BNO5; IUPAC Name: [(2R)-1-[(1R)-1-[(1R,5S,7E,11S,13S,16R,17R,24S,25R,27R,31R,33S,36R)-11,31-dihydroxy-12,16,12,25,32,36-heptamethyl-3,2,2-dioxo-1,8,19,20,23,26,37,38,40,41-nonaaxa-19-boruanudahetcyclo[17,17,1,11,13,12,19,113,17,124,27,017,21]hentetracont-7-en-5-y]ethoxyl-3-methyl-1-oxobutan-2-yl]azanuin | Banker & Carmeli, 1998; Gupta, 2012 |
| Scytonema varium | Scytovirin          | MF: C60H46N4O8S; IUPAC Name: (4S)-4-[[2S]-4-amino-2-[[2S]-2-[[2S,3R]-2-[[2S,3R]-2-[[2S,1-2-[[2S,2-[[2S,2-[2-aminoacetyl]amino]-3-hydroxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-[4-hydroxyphenyl]propanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-[[2S]-1-[[2S]-4-amino-1-[[2S]-4-amino-1-[[2S]-2-(carboxymethylcarbonyl)pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid | Shi et al., 1999 |
| Symploca genus | Largazole             | MF: C41H39N5O5; IUPAC Name: S-[[(E)-4-[[5R,8S,11S]-5-methyl-6,9,13-trioxo-8-propan-2-yl]-10-oxa-3,17-dithia-7,14,19,20-tetrazatricycl[14.2.1.12.5]icos-1(18),2(20),16(19)-trien-11-yl]but-3-enyl] octanethioate | Luesch et al., 2001 |
| Nostoc sp.   | Apratoxin A           | MF: C80H78N8O8S; IUPAC Name: (2S,3S,5S,7S,10S,16S,19S,22S,25E,27S)-16-[[2S]-2-butyl-7-tert-buty1-3-hydroxy-22-[[4-methoxyphenyl]methyl]-2,5,17,19,20,25-hexamethyl-8-oxa-29-thia-14,17,20,23,30-pentazatricycl[25.2.1.0.10.14]triaconta-1(30),25-diene-9,15,18,21,24-pentone | Grinberg et al., 2002 |
| BGA Spp.    | Anticancer Compounds | Chemical Structure                                                                                                                                                                                                 | References                        |
|-------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| *Dolabella auricularia* | Dolastatin 15        | MF: C_{20}H_{33}N_{10}O_{9}  
MW: 837.1g/mol  
IUPAC Name: [(2S)-1-[(2S)-2-benzyl-3-methoxy-5-oxo-2H-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2S)-1-[(2S)-1-[(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]pyrrroline-2-carbonyl]pyrrroline-2-carboxylate | Stevenson et al., 2002            |
| Cyanobacteria | Astaxanthin           | -                                                                                                                                                                                                                  | Chen et al., 2003                  |
| *Nostoc* sp. | Cryptophycin          | MF: C_{23}H_{33}ClN_{10}O_{9}  
MW: 655.2g/mol  
IUPAC Name: (3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraene | Back & Liang 2005; Medina et al., 2008 |
| *L. majusculata* | Curacin A             | MF: C_{30}H_{38}N_{10}O_{8}  
MW: 373.6g/mol  
IUPAC Name: (4R)-4-[(1Z,5E,7E,11R)-11-methoxy-8-methyltetradeca-1,5,7,13-tetraenyl]-2-[(1R,2S)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole  
Isomeric SMILES: C/C\@H]1C/C\@H]1C2=NC\@H](CS2)/C=C/CC/C=C/C=C/C=C/C=C/C@H](CC=CC)OC | Xiong et al., 2006                 |
| *Lyngbya* sp. | Dragonamide C         | MF: C_{27}H_{33}N_{10}O_{8}  
MW: 619.8g/mol  
IUPAC Name: (E)-N-[(2S)-1-[(2S)-1-[(2S)-1-[(2S)-1-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methoxy-N-methyloct-2-en-7ynamide | Gunasekera et al., 2008            |
| *Lyngbya* sp. | Dragonamide D         | MF: C_{27}H_{33}N_{10}O_{8}  
MW: 605.8g/mol  
IUPAC Name: N-[(2S)-1-[(2S)-1-[(2S)-1-[(2S)-1-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-N-methyl-3-oxooct-7-ynamide | Gunasekera et al., 2008            |
2.1.6 Antiviral Potential including SARS-CoV-2

The globe is so much affected by the dreadful diseases caused by infection of viruses such as HIV-acquired immune deficiency syndrome. There is also another viral deadly disease that is dengue which may have many consequences. Despite two former major outbreaks of coronavirus infections i.e. the SARS and MERS, the world is still underprepared to effectively manage the current COVID-19 pandemic outbreak. The researchers were in search of a novel and potent drug which will be able to resist those deadly and dreadful viral infections throughout the world. Scientists have now invented novel, potent, and safe anti-viral agents that are very useful in this urgent situation. Recently there is a new scientific treatment or therapy which is named highly active antiretroviral therapy in short HAART. This is triple therapy which is very fruitful and capable in the treatment of HIV infections which is very helpful and makes control and resistance power in carcinogenic treatment. This therapy can create strong viral resistance. But this therapy cannot stop the viral agent which is causing such kinds of issues. BGA species are also known to produce substances that have been proved to be anti-HIV, therefore can be exploited in therapy against AIDS (Schaeffer & Krylov, 2000; Carpine & Sieber, 2021)

Gustafson et al. (1989) used a tetrazolum-based micro-culture to screen extracts of cultured marine cyanobacteria, Lyngbyalager heimii, and Phormedium tenue, for the inhibition of HIV-1. This led to the discovery of sulfonic acid containing glycolipids as a new class of HIV-1 inhibitory compounds. Other cyanobacteria, Phormedium cebennse, Oscillatoria raciborskii, Scytonem aburanicum, Calothrix elenkinii, and Anabaena variabilis, gave extracts that inhibited HIV-1 and gave positive tests for the presence of sulfolipids.

Compounds and extracts with anti-HIV activity are also active against other retroviruses such as Herpes simplex virus (HSV) and respiratory syncytial virus, but the amount of antiviral activity varies with the compound and the virus. Most of the research has focused on sulphated homopolysaccharides and heteropolysaccharides, sulfoglycolipids, carrageenans, fucoidan, sesquiterpene hydroquinones, and other classes of compounds with an anti-HIV activity that has been isolated from algae have received less attention. Hayashi et al. (1996) isolated calcium spirulan, a sulfated polysaccharide obtained from a marine blue-green alga, Spirulina platensis which inhibited the Herpes simplex virus. Subsequently, Ayeunie et al. (1998) determined that an aqueous extract of S. platensis, at a concentration that was non-toxic to human cells, inhibited syncytium formation and HIV-1
Pharmaceutical potential of laboratory grown cultures of blue-green algae: a comprehensive review and future possibilities

replication in human T-cell lines, peripheral blood mononuclear cells, and Langerhans cells. The antiviral effects of polysaccharides from marine algae towards mumps virus and influenza B virus were reported by Gerber et al. (1958). Subsequently, polysaccharides fractions from extracts of red algae were found to inhibit the herpes simplex virus (HSV). Similarly, Boyd et al. (1997) isolated Cyanovirin-N from an aqueous cellular extract of cyanobacterium Nostoc ellipsosporum which has been proved to be antiviral. Lau et al., (1993) reported that the lipophilic and hydrophilic extracts of over 900 strains of cultured blue-green algae in vitro for their ability to inhibit the reverse transcriptases of avian myeloblastosis virus (Table 7)

Various compounds have been isolated from a variety of blue-green algae BGA-derived polysaccharides that have been reported for the inhibition of SARS-CoV-2 (Sami et al., 2021). Few organizations are actively involved in developing algae-based edible vaccines for SARS-CoV-2 (Jafari et al., 2021) (Table 8)

### 2.1.7 Antidiabetic Potential of BGA

Blue-green algae are known to exhibit potential antidiabetic properties. In a study conducted by Priatni et al. (2016) methanol extract of marine cyanobacterial strains such as Oscillatoria limnetica, Coelastrella sp., Oscillatoria sp., Chroococcus sp., Leptolyngbya sp., Pseudoanabaena sp., Lyngbya sp., Aphanothece sp., Phormidium sp, and Synechococcus sp. have potential antidiabetic potential. The metabolites of Pseudoanabaena sp. showed the highest α-glucosidase inhibition. In another study, Egyptian Scientists evaluated extracts of Fischerella sp. BS1-EG for antidiabetic

| BGA Sp.       | Anti Viral Compound | Chemical Structure | References                  |
|---------------|---------------------|--------------------|-----------------------------|
| Nostoc ellipsosporum | Cyanovirin-N        | Boyd et al., 1997;; Bewley, 2001 |
| Microcystis aeruginosa | Microvirin         | Kehr et al., 2006  |
| Scytonema varium | Microcystis Viridis Lectin | Bokesch et al., 2003 |
| M. viridis NIES-02 | Microcystis Viridis Lectin | NA | Yamaguchi et al., 1999 |
| Arthrospira platensis | Calcium Spirulan | NA | Hayashi et al., 1996 |
potential and have reported certain bioactive compounds responsible for the activity (Ahmed et al., 2018). In a recent study, Sridhar et al. (2021) have evaluated phycocyanin of *S. platensis* for its antidiabetic potential by assessing α-amylase and β-glucosidase enzyme inhibition using spectroscopy techniques. In this *in vitro* test, significant Antidiabetic activity (88%) was observed at a concentration of 250 μg/ml. In some studies, lesser antidiabetic properties have been reported, like Ghosh et al. (2016) evaluated in vitro antidiabetic properties of molecules from *Lyngbya*, *Microcoleus*, and *Synechocystis* sp. by α-amylase inhibition method and stated the lesser enzyme inhibition effect. Similarly, Xu et al. (2012) described the lowest α-amylase enzyme inhibition activity of *Phlorotannins* pigments extracted from Eckloniakurome. However, Hwang et al. (2014) reported 65 - 80% inhibitory activity at the concentration of 250 μg/ml while this was reported 51 - 67% at the dose of 200 μg/ml dose of *S. platensis* phycocyanin. Lesser enzyme inhibition even in higher concentrations was reported in a study conducted by Priatni et al. (2016).

### 2.1.8 Anti-inflammatory Activity of BGA

Blue-Green Algae contain a significant amount of carotenoids *i.e.* β-carotene, lycopene, lutein having antioxidant properties. By the quenching action on the reactive oxygen species, these carotenoids also have anti-inflammatory activity. This anti-inflammatory activity might be due to the presence of phycocyanin, a photo harvesting pigment. Further, the anti-inflammatory effect seemed to be the result of leucotriene formation inhibition by phycocyanin, an inflammatory metabolite of arachidonic acid (Romay et al., 1999). *Aphanizomenon flos-aquae* decrease the level of arachidonic acid. Further, *A. flos-aquae* and *Spirulina* contain significant amount of omega-3 alpha linolenic acid which inhibits the formation of inflammatory prostaglandins and arachidonate metabolites (Figure 15).

### 3 Conclusion and Future possibilities

BGA are groups of extraordinary, diverse, gram-negative, oxygenic, photosynthetic prokaryotic microscopic organisms.
Blue-green algae are found all over the world, showing remarkable ecological diversity of habitats such as freshwater, terrestrial, marine, hot spring, etc. These BGA are also widely distributed in the polar region such as the Arctic, Antarctic, Southern Ocean, and the Himalayas. Several studies have been conducted for the isolation and identification of Blue-Green algae from the water, soil, sediments, algal mats, etc. using advanced morphological, physiological, and molecular characterization techniques. Various selective media are known for their Cultivation. It has been now proven that BGA offers a great opportunity as these are considered to be one of the potential organisms useful to mankind in many ways. They exhibit diverse biological activities (Antibacterial, Antifungal, Anticancer, Antiviral Antidiabetic, and many more). Various bioactive molecules have been reported by researchers globally. In pharmaceutical companies especially in the new drug discovery research division, for the last many year's research is going on at various levels starting from extraction, purification, and identification of new compounds or drugs from various species of BGA. The major challenge in front of the current world is to fight effectively against the new emerging diseases and microbes specifically WHO priorities list of multiple antibiotic-resistant bacteria, microbial infections including SARS-CoV-2 virus and Cancer, etc., and to discover new advanced compounds for mankind and society. At the same time, there is an urgent need to think from basic to applied research to commercialize several value-added products. The use of nanomaterials to enhance biological activity could be one of the ways. Inventions of these drugs using nanotechnology can lead to the development of novel pharmaceuticals. Based on the cultures of cells, activities of enzymes, and receptors binding with ligands, various new technologies are invented to develop novel things of miniaturized screens. As a result, there is a conformational analysis, i.e., an analysis of the spatial arrangement of the component atom within a molecule that can be rotated about one or more single bonds. The known ligands result in the development of new compounds of structure-based drug design. Hence, the pharmaceutical potential of blue-green algae deserves more scientific attention and interdisciplinary research, and BGA strains from still unexplored and extreme habitats such as the Antarctic, Arctic, and the Himalayas can serve as good candidates in this regard.

Authors’ contributions

All authors contributed significantly to the conception and design of the study, the interpretation of data, and the drafting and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge the support of Dr. Ashok K. Chauhan, Founder President, Amity Universe, for his constant support and encouragement. The authors also thank Dr. Atul Chauhan, Chancellor, Amity University, Uttar Pradesh, for providing all the required facilities.

Conflict of Interest

The authors hereby declare no conflict of interest.

Funding support

The authors declare that they have no funding support for this study.

References

Ahmed BE, Badawi MH, Mostafa SS, Higazy AM (2018) Human anticanic and antidiabetic activities of the cyanobacterium *Fischerella* sp. BS1-EG isolated from River Nile, Egypt. International Journal Current Microbiology and Applied Science 7(1): 3473-3485.

Allen MB, Arnon DI (1955) Studies on nitrogen fixing blue green algae. I. growth and nitrogen fixation in *Anabaena cylindrica*. Plant Physiology 30: 366-372.

Al-Saman MA, Daleib NM, Ibrahim MR, Nasr MY, Tayel AA, Hamouda RA (2020) In vitro and in vivo hypolipidemic properties of the aqueous extract of *Spirulina platensis*, cultivated in colored flasks under artificial illumination. PeerJ 8: e10366.

Andrianasolo EH, Gross H, Goeger D, Musafija-Girt M, McPhail K, Leal RM, Mooberry SL, Gerwick WH (2005) Isolation of swinhohide A and related glycosylated derivatives from two field collections of marine cyanobacteria. Organic letters 7(7):1375-8.

Asthana RK, Tripathi MK, Srivastava A, Singh AP, Singh SP, Nath G, Srivastava R, Srivastava BS (2009) Isolation and identification of a new antibacterial entity from the Antarctic cyanobacterium Nostoc CCC 557. Journal of Applied Phycology 21(1):81-8.

Atanasov AG, Zotechev SB, Dirsch VM, Supuran CT (2021) Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery 20(3):200-216. doi: 10.1038/s41573-020-00114-z.

Ayehunie S, Belay A, Baba TW, Ruprecht RM (1998) Inhibition of HIV-1 replication by an aqueous extract of *Spirulina platensis* (Arthospira platensis). Journal of Acquired Immune Deficiency Syndrome 18(1): 7-12.

Back S, Liang J (2005) Production of cryptophycin from blue-green algae. Journal of Young Investigator 12:1654-1673.
Banker R, Carmeli S (1998) Tenuecyclamides A–D, Cyclic Hexapeptides from the Cyanobacterium Nostoc spongiaeforme var. tenue. Journal of Natural Products 61(10):1248-51.

Basu S, Gledhill M, de Beer D, Matondkar SP, Shaked Y (2019) Colonies of marine cyanobacteria Trichodesmium interact with associated bacteria to acquire iron from dust. Communications Biology 2(1): 1-8.

Becher PG, Keller S, Jung G, Süssmuth RD, Jüttner F (2007) Insecticidal activity of 12-epi-hapalindole J isonitrile. Phytochemistry 68(19):2493-7.

Bellahcen TO, AAmiri A, Touam I, Hnimid F, El Amrani A, Cherif A, Cherki M (2020) Evaluation of Moroccan microalgae: Spirulina platensis as a potential source of natural antioxidants. Journal of Complementary and Integrative Medicine 17(3). https://doi.org/10.1515/jcim-2019-0036

Bellinger EG, Sigee DC (2015) Freshwater algae: identification, enumeration and use as bioindicators. John Wiley & Sons.

Bernardini S, Tiezzi A, LaghezzaMasci V, Ovidi E (2018) Natural products for human health: an historical overview of the drug discovery approaches. Natural Product Research 32(16): 1926-1950.

Berry JP, Gantar M, Gawley RE, Wang M, Rein KS (2004) Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from a freshwater species of Lyngbya isolated from the Florida Everglades. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 139(4):231-8.

Bewley CA (2001) Solution structure of a cyanovirin-N: Manα1-2Man complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure 9(10):931-40.

Bhadury P, Wright PC (2004) Exploitation of marine algae: biogenic compounds for potential antifouling applications. Planta 219(4):561-78.

Bokesch HR, O’Keefe BR, McKee TC, Pannell LK, Patterson GM, Gardella RS, Sowder RC, Turpin J, Watson K, Buckheit RW, Boyd MR (2003) A potent novel anti-HIV protein from the cultured cyanobacterium Scytoneumavarium. Biochemistry 42(9):2578-84.

Boll HC (1949) The morphology of Chlamydomonas chlamydogama, sp. nov. Bulletin of the Torrey Botanical Club 1:101-8.

Bonjouklian R, Moore RE, Patterson GM (1988) Acid-catalyzed reactions of hapalindoles. The Journal of Organic Chemistry 53(25):5866-70.

Boyd MR, Gustafson K, McMahon JB, Shoemaker R (1996) Discovery of cyanovirin-N, a novel HIV-inactivating protein from Nostoc ellipsosporum that targets viral gp120. International Conference on AIDS 11: 71-71.

Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O’Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera ML, Laurencot CM, Currens MJ (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial Agents and Chemotherapy 41(7):1521-30.

Bui HT, Jansen R, Pham HT, Mundt S (2007) Carbamidocyclophanes A–E, Chlorinated Paracyclophanes with Cytotoxic and Antibiotic Activity from the Vietnamese Cyanobacterium Nostoc sp. Journal of Natural Products 70(4):499-503.

Cardellina II JH, Kirkup MP, Moore RE, Mynderse JS, Seff K, Simmons CJ (1979a) Hyellazone and chlorohyellazole, two novel carbazoles from the blue-green alga hyellaecaspitosa born. et flah. Tetrahedron Letters 20(51):4915-4916.

Cardellina JH, Marner FJ, Moore RE (1979b) Seaweed dermatitis: structure of lyngbyatoxin A. Science 204(4389):193-5.

Carmichael WW (1992) Cyanobacteria secondary metabolites—the cyanotoxins. Journal of Applied Bacteriology 72(6):445-59.

Carpine R, Sieber S (2021) Antibacterial and antiviral metabolites from cyanobacteria: their application and their impact on human health. Current Research in Biotechnology 3: 65-81.

Chatterjee PM, Tiwari DP, Datta S, Chakrabarty S, Raval R, Dubey AK (2019) Probing into methylation of the cyanotoxins. Journal of Applied Bacteriology 127(6):1521-30.

Chauhan A, Jindal T (2020) Microbiological Methods for Water, Soil and Air Analysis. In: Microbiological Methods for Environment, Food and Pharmaceutical Analysis 2020, Springer, Cham. Pp. 93-196.

Chauhan A, Ranjan A, Basniwal RK, Jindal T (2022) Cytotoxic and Antibiotic Properties of Cyanobacterial Extracts. In: Jindal T (eds) New Frontiers in Environmental Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-030-72173-2_4.
Chen X, Smith GD, Waring P (2003) Human cancer cell (Jurkat) killing by the cyanobacterial metabolite calothrixin A. Journal of Applied Phycology 15(4):269-77.

Cheng YI, Chou L, Chiu YF, Hsueh HT, Kuo CH, Chu HA (2020) Comparative genomic analysis of a novel strain of Taiwan hot-spring cyanobacterium Thermosynechococcus sp. CL-1. Frontiers in microbiology 11: 82.

Chittapun S, Jonjaroen V, Khunrangsee K, Charoenrat T (2020) C-phycocyanin extraction from two freshwater cyanobacteria by freeze thaw and pulsed electric field techniques to improve extraction efficiency and purity. Algal Research 46: 101789.

Choi H, Engene N, Smith JE, Preskitt LB, Gerwick WH (2010) Crossbyanols A–D, toxic brominated polyphenyl ethers from the Hawai`ian bloom-forming Cyanobacterium Leptolyngbya cross byana. Journal of Natural Products 73(4):517-22.

Chorus I, Falconer IR, Salas JH, Bartram J (2000) Health risks caused by freshwater cyanobacteria in recreational waters. Journal of Toxicology and Environmental Health Part B: Critical Reviews 3(4):323-47.

Chu SP (1942) The influence of the mineral composition of the medium on the growth of planktonic algae: part I. Methods and culture media. The Journal of Ecology 1:284-325.

Dimri AG, Prasad R, Chauhan A, Aggarwal ML, Varma A (2018) Characterization of soil actinomycete isolate against gram-positive and gram-negative food borne bacteria. Indian Journal of Environmental Protection 38: 1004-1015.

Duan NT, Rickards RW, Rothschild JM, Smith GD (2000) Allelopathic actions of the alkaloid 12-epi-hapalindole E isonitrile and calothrixin A from cyanobacteria of the genera Fischerella and Calothrix. Journal of Applied Phycology 12(3):409-16.

Duy TN, Lam PKS, Shaw GR, Connell DW (2000) Toxicology and Risk Assessment of Freshwater Cyanobacterial (Blue-Green Algal) Toxins in Water. In: Ware GW (Eds.) Reviews of Environmental Contamination and Toxicology. Reviews of Environmental Contamination and Toxicology, vol 163. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-6429-1_3.

El-Sheikh MM, Hassan LH, Morsi HH (2021) Evaluation of antimicrobial activities of blue-green algae-mediated silver and gold nanoparticles. RendicontiLincei. ScienzeFisiche e Naturali 18:1-3.

Falch BS, König GM, Wright AD, Sticher O, Angerofer CK, Pezzuto JM, Bachmann H (1995) Biological activities of cyanobacteria: evaluation of extracts and pure compounds. Planta Medica 61(04):321-8.

Fatima N, Ahmad IZ, Chaudhry H (2017) Alterations in the antibacterial potential of Synecococcus spp. PCC7942 under the influence of UV-B radiation on skin pathogens. Saudi Journal of Biological Sciences 24(7): 1657-1662.

Fogg G (1965) Algal culture and phytoplankton ecology. University of Wisconsin Press, Madison Pp. 126.

Gabr GA, El-Sayed SM, Hikal MS (2020) Antioxidant Activities of Phycocyanin: A Bioactive Compound from Spirulina platensis. Journal of Pharmaceutical Research International 32(2): 73-85.

Gademann K, Portmann C (2008) Secondary metabolites from cyanobacteria: complex structures and powerful bioactivities. Current Organic Chemistry 12(4):326-341.

Gamal S, Abd El Baky HH, Saleh MA (2020) Egyptian Arthospira phytosterols: production, identification, antioxidant and antiproliferative activities. Notulae Botanicae HortiAgrobotanici Cluj-Napoca 48(2): 666-680.

Gara-Ali M, Zili F, Hosni K, Ouada HB, Ben-Mahrez K (2021) Lipophilic extracts of the thermophilic cyanobacterium Leptolyngbya sp. and chlorophyte Graesiella sp. and their potential use as food and anticancer agents. Algal Research 60: 102511.

Gerber P, Dutcher JD, Adams EV, Sherman JH (1958) Protective effect of seaweed extracts for chicken embryos infected with influenza B or mumps virus. Proceedings of the Society for Experimental Biology and Medicine 99(3): 590-593.

Gerwick WH, Mrozek C, Moghaddam MF, Agarwal SK (1989) Novel cytotoxic peptides from the tropical marine cyanobacterium Hormothamnion enteromorphoides 1. Discovery, isolation and initial chemical and biological characterization of the hormothammins from wild and cultured material. Experientia 45(2):115-21.

Gheda SF, Ismail GA (2020) Natural products from some soil cyanobacterial extracts with potent antimicrobial, antioxidant and cytotoxic activities. Anais da Academia Brasileira de Ciências 92(2):e20190934. doi: 10.1590/0001-37652020190934.

Ghosh T, Bhayani K, Paliwal C, Maurya R, Chokshi K, Pancha I, Mishra S (2016) Cyanobacterial pigments as natural antihyperglycemic agents: an in vitro study. Frontiers in Marine Science 10(3):146.

Grinberg M, Sarig R, Zaltsman Y, Frumkin D, Grammatikakis N, Reuveny E, Gross A (2002) tBID Homooligomerizes in the

Journal of Experimental Biology and Agricultural Sciences
http://www.jebas.org
mitochondrial membrane to induce apoptosis. Journal of Biological Chemistry 277(14):12237-45.

Guerreiro A, Andrade MA, Menezes C, Vilarinho F, Dias E (2020) Antioxidant and Cytoprotective Properties of Cyanobacteria: Potential for Biotechnological Applications. Toxins 12(9): 548.

Gunasekera SP, Ross C, Paul VJ, Matthew S, Luesch H (2008) Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown *Lyngbya polychroa*. Journal of Natural products 71(5):887-90.

Gustafson KR, Cardellina II JH, Fuller RW, Weislow OS, Kiser RF, Sander KM, Patterson GML, Boyd MR (1989) AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). Journal of the National Cancer Institute 81: 1254-1258.

Gustafson KR, Sowder R, Henderson L, Pannell L, Cardellina J, McMahon J, Shoemaker R, Boyd M (1996) Sequence determination and chemical characteristics of a novel anti-HIV protein, Cyanovirin-N, isolated from the cyanobacterium *Nostoc ellipsosporum*. International Controversies on AIDS 11: 70.

Hayashi K, Hayashi T, Kojima I (1996) A natural sulfated polysaccharide, calcium spirulinate, isolated from *Spirulina platensis*: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Research and Human Retroviruses 12(15):1463-71.

Hirata K, Yoshitomi S, Dwi S, Iwabe O, Mahakhant A, Polchai J, Miyamoto K (2003) Bioactivities of nostocene A produced by a freshwater cyanobacterium *Nostoc spongiaeforme* TISTR 8169. Journal of Bioscience and Bioengineering 95(5):512-7.

Hokmollahi F, Riahi H, Soltani N, Shariatmadari Z, Hakimi Meybodi MH (2016) A taxonomic study of blue-green algae based on morphological, physiological and molecular characterization in Yazd province terrestrial ecosystems (Iran). Rostanli 16(2): 152-163.

Hwang P, Hung Y, Tsai Y, Chien SY, Kong Z (2014) The brown seaweed *Sargassum hemiphyllum* exhibits α-amylase and α-glucosidase inhibitory activity and enhances insulin release in vitro. Cytotechnology 67: 653–660.

Inderjit DK, Dakshini KM (1994) Algal allelopathy. The Botanical Review 60:182-96.

Ishibashi M, Moore RE, Patterson GM, Xu C, Clardy J (1986) Scytophyccins, cytotoxic and antimycotic agents from the cyanophyte Scytoneumpsuedohofmanni. The Journal of Organic Chemistry 51(26):5300-6.

Ishida K, Matsuda H, Murakami M, Yamaguchi K (1997) Kawaguchipeptin B, an antibacterial cyclic undecapeptide from the cyanobacterium *Microcystis aeruginosa*. Journal of Natural Products 60(7):724-6.

Jafari Porzani S, Konur O, Nowruz I (2021) Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19. Journal of Biomolecular Structure and Dynamics 1-17. doi: 10.1080/07391102.2021.1899050.

Jaki B, Orjala J, Heilmann J, Linden A, Vogler B, Sticher O (2000) Novel Extracellular Diterpenoids with Biological Activity from the Cyanobacterium *Nostoc commune*. Journal of natural products 63(3):339-43.

Jaki B, Zerbe O, Heilmann J, Sticher O (2001) Two novel cyclic peptides with antifungal activity from the cyanobacterium *Tolyphorhis byssoides* (EAWAG 195). Journal of Natural Products 64(2):154-8.

Jaspars M, Lawton LA (1998) Cyanobacteria-a novel source of pharmaceuticals. Current opinion in Drug Discovery & Development (1):77-84.

Jimenez-Lopez C, Pereira AG, Lourenço-Lopes C, Garcia-Oliveira P, Cassani L, Fraga-Corral M, Simal-Gandara J (2021) Main bioactive phenolic compounds in marine algae and their mechanisms of action supporting potential health benefits. Food Chemistry 341: 128262.

Jo SW, Do JM, Na H, Hong JW, Kim IS, Yoon HS (2020) Assessment of biomass potentials of microalgal communities in open pond raceways using mass cultivation. PeerJ 8: e9418.

Jones GJ, Korth W (1995) In situ production of volatile odour compounds by river and reservoir phytoplankton populations in Australia. Water Science and Technology 31(11):145-51.

Kaiwan-arpon P, Hai PD, Thu NT, Annachhatre AP (2012) Cultivation of cyanobacteria for extraction of lipids. Biomass and Bioenergy 44: 142-149.

Kajiwamak SI, Kanzaki H, Kawazu K, Kobayashi A (1998) Nostofungicidine, an antifungal lipopeptide from the field-grown terrestrial blue-green alga *Nostoc commune*. Tetrahedron Letters 39(22):3737-3740.

Kaushik P, Abhishek C, Pankaj G (2009) Screening of *Lyngbya juscules* for potential antibacterial activity and HPTLC analysis of active methanolic extract. Journal of Pure and Applied Microbiology 3(1): 169-174.
Kaushik P, Chauhan A (2008a) Antibacterial Potential of aqueous and organic extracts of N. Commune: A Cyanobacterium. VEGETOS 21(1): 77-80.

Kaushik P, Chauhan A (2008b) In vitro antibacterial activity of laboratory grown culture of Spirulina platensis. Indian Journal of Microbiology 48(3): 348-352.

Kaushik P, Goyal P, Chauhan A, Chauhan G (2010) In vitro evaluation of antibacterial potential of dry fruit extracts of Elettaria cardamomum Maton (ChhotiElaichi). Iranian Journal of Pharmaceutical Research 9(3): 287.

Kehr JC, Zilliges Y, Springer A, Disney MD, Ratner DD, Bouchier C, Seeberger PH, De Marsac NT, Dittmann E (2006) A mannan binding lectin is involved in cell–cell attachment in a toxic strain of Microcystis aeruginosa. Molecular Microbiology 59(3):893-906.

Khatoon H, Leong LK, Rahman NA, Mian S, Begum H, Banerjee S, Endut A (2018) Effects of different light source and media on growth and production of phycobiliprotein from freshwater cyanobacteria. Bioresource Technology 249: 652-658.

Larsen LK, Moore RE, Patterson GM (1994) β-Carbolines from the blue-green alga Dichothrix baueriana. Journal of Natural Products 57(3):419-21.

Lau AF, Siedlecki J, Anleitner J, Patterson GM, Caplan FR, Moore RE (1993) Inhibition of reverse transcriptase activity by extracts of cultured blue-green algae (cyanophyta). Planta Medica 59: 148-151.

Li LY, Wu W, Chen S, Gu JW, Li XL, Song HJ, Du F, Wang G, Zhong CQ, Wang XY, Chen Y, Shah R, Yang HM, Cai Q (2020) Digestive system involvement of novel coronavirus infection: Prevention and control infection from a gastroenterology perspective. Journal of Digestive Diseases 21(4):199-204. https://doi.org/10.1111/1751-2980.12862.

Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP (2006) Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrobial Agents and Chemotherapy 50(10):3250-3259.

Loya S, Reshef V, Mizrachi E, Silberstein C, Rachamim Y, Carmeli S, Hizi A (1998) The inhibition of the reverse transcriptase of HIV-1 by the natural sulfglycolipids from cyanobacteria: contribution of different moieties to their high potency. Journal of Natural Product 61: 891-895.

Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symplaca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. Journal of Natural Products 64(7):907-10.

MacMillan JB, Ernst-Russell MA, De Ropp JS, Molinski TF (2002) Lobocyclamides A–C, Lipopeptides from a cryptic cyanobacterial mat containing Lyngbya confervoides. The Journal of Organic Chemistry 67(23):8210-5.

MacMillan JB, Molinski TF (2005) Majusculoic acid, a brominated cyclopropyl fatty acid from a marine cyanobacterial mat assemblage. Journal of Natural Products 68(4):604-6.

Marrez DA, Sultan YY (2016) Anti-fungal activity of the cyanobacterium Microcystis aeruginosa against mycotoxigenic fungi. Journal of Applied Pharmaceutical Science 6(11): 191-198.

Mason CP, Edwards KR, Carlson RE, Pignatelto J, Gleason FK, Wood JM (1982) Isolation of chlorine-containing antibiotic from the freshwater cyanobacterium Scytonema hofmanni. Science 215(4531):400-2.

Matern U, Oberer L, Falchetto RA, Erhard M, König WA, Herdmann M, Weckesser J (2001) Scyptolin A and B, cyclic depsipeptides from axenic cultures of Scytonema hofmanni. PCC 7110. Phytochemistry 58(7):1087-95.

Mathew B, Sankaranarayanan R, Nair PP, Varghese C, Somanathan T, Amma BP, Amma NS, Nair MK(1995) Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutrition and Cancer 24: 197-202.

Medina RA, Goeger DE, Hills P, Mooberry SL, Huang N, Romero LI, Ortega-Barria E, Gerwick WH, McPhail KL (2008) Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. Journal of the American Chemical Society 130(20):6324-5.

Metting B, Pyne JW (1986) Biologically active compounds from microalgae. Enzyme and Microbial Technology 8(7):386-94.

Mishima T, Murata J, Toyoshima M, Fujii H, Nakajima M, Hayashi T, Kato T, Saiki I (1998) Inhibition of tumor invasion and metastasis by calciumspirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis. Clinical & Experimental Metastasis 16(6):541-550.

Mo S, Krunic A, Chlipala G, Orjala J (2009) Antimicrobial amiguine isonitriles from the cyanobacterium Fischerella ambiguia. Journal of Natural Products 72(5):894-9.
Moon SS, Chen JL, Moore RE, Patterson GM (1992) Calophycin, a fucoidal cyclic decapeptide from the terrestrial blue-green alga Calothrix fusa. The Journal of Organic Chemistry 57(4):1097-103.

Moore RE (1982) Toxins, anticancer agents, and tumor promoters from marine prokaryotes. Pure and Applied Chemistry 54(10):1919-34.

Moore RE, Patterson GM, Carmichael WW (1988) New pharmaceuticals from cultured blue-green algae. Biomedical Importance of Marine Organisms 13:143-50.

Moore RE, Yang XQ, Patterson GM (1987) Fontonamide and anhydrohapaloxindole A, two new alkaloids from the blue-green alga Hapalosiphon fontinalis. The Journal of Organic Chemistry 52(17):3773-3777.

Müller D, Krick A, Kehraus S, Mehner C, Hart M, Küpper FC, Saxena K, Prinz H, Schwalbe H, Janning P, Waldmann H (2006) Brunsvicamides A-C: Sponge-Related Cyanobacterial Peptides with Mycobacterium tuberculosis Protein Tyrosine Phosphatase Inhibitory Activity. Journal of Medicinal Chemistry 49(16):4871-8.

Mundt S, Kreitlow S, Jansen R (2003) Fatty acids with antibacterial activity from the cyanobacterium Oscillatoria redekei HUB 051. Journal of Applied Phycology 15(2):263-7.

Nagatsu A, Kajitani H, Sakakibara J. Muscoride A (1995) A new oxazole peptide alkaloid from freshwater cyanobacterium Nostoc muscorum. Tetrahedron Letters 36(23):4097-100.

Nainangu P, Antonyraj APM, Subramanian K, Kaliyaperumal S, Gopal S, Renuka PS (2020) In vitro screening of antimicrobial, antioxidant, cytotoxic activities, and characterization of bioactive substances from freshwater cyanobacteria Oscillatoria sp. SSCM01 and Phormidium sp. SSCM02. Biocatalysis and Agricultural Biotechnology 29: 101772.

Natarajan C, Prasanna R, Gupta V, Dureja P, Nain L (2012) Characterization of the fucoidal activity of Calothrix elenkini using chemical methods and microscopy. Applied Biochemistry and Microbiology 48(1):51-57.

Neuhof T, Schmieder P, Preussel K, Dieckmann R, Pham H, Bartl F, von Döhren H (2005) Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacterium Hassallia sp. Journal of Natural Products 68(5):695-700.

Niveshika, Verma E, Mishra AK, Singh AK, Singh VK (2016) Structural elucidation and molecular docking of a novel antibiotic compound from cyanobacterium Nostoc sp. MGL001. Frontiers in microbiology 7:1899.

Padmini N, Ajilda AA, Prabakaran P, Sivakumar N, Selvakumar G (2021) Efficacy of marine cyanobacterium Oxytrichaianum ALU PBC5 against multi drug resistant Gram negative pathogens. Journal of Applied Microbiology 130(1):50-60.

Petersen LE, Kellermann MY, Schupp PJ (2020) Secondary metabolites of marine microbes: From natural products chemistry to chemical ecology. Youmares 9-The Oceans: Our Research, Our Future 159.

Ploutno A, Carmeli S (2000) Nostocyclyne A, a novel antimicrobial cyclophane from the cyanobacterium Nostoc sp. Journal of Natural Products 63(11):1524-6.

Pratt R, Daniels TC, Eiler JJ, Gunisson JB, Kumler WD, Oneto JF, Strait LA, Sloop HA, Hardin GJ, Milner HW, Smith JH (1944) Chlorellin, an antibacterial substance from Chlorella. Science 99 (2574):351-352.

Priatni S, Budiwati TA, Ratnaningrum D, Kosasih W, Andryani R, Susanti H, Susilaningsih W (2016) Antidiabetic screening of some Indonesian marine cyanobacteria collection. Biodiversitas 17(2): 641-646.

Pringsheim E (1946) Pure Cultures of Algae. Cambridge University Press London Pp. 119.

Prinne MR, Moore RE, Levine IA, Patterson GM (1992) Westiellamide, a bistratamide-related cyclic peptide from the blue-green alga Westiellopsis prolifica. Journal of Natural Products 55(1):140-2.

Radkova M, Stefanova K, Uzunov B, Gärtner G, Stoyneva-Gärtner M (2020) Morphological and molecular identification of microcystin-producing cyanobacteria in nine shallow Bulgarian water bodies. Toxins 12(1): 39.

Radzi R, Muangmai N, Broady P, Wan Omar WM, Lavoue S, Convey P, Merican F (2019) Nodosilinea sp. Nov. (Leptolyngbyaceae, Synechococcales), a new terrestrial cyanobacterium isolated from mats collected on Signy Island, South Orkney Islands, Antarctica. PloSone 14(11): e0224395.

Raveh A, Carmeli S (2007) Antimicrobial ambiguines from the cyanobacterium Fischerella sp. collected in Israel. Journal of Natural Products 70(2):196-201.

Rego A, Raio F, Martins TP, Ribeiro H, Sousa AG, Séneca J, Magalhães C (2019) Actinobacteria and cyanobacteria diversity in terrestrial antarctic microenvironments evaluated by culture-
dependent and independent methods. Frontiers in Microbiology 10: 1018.

Reshef V, Mizrachi E, Maretzki T, Silberstein C, Loya S, Hizi A, Carmeli S (1997) New acetylated sulfoglycolipids and digalactolipids and related known glycolipids from cyanobacteria with potential to inhibit the reverse transcriptase of HIV-1. Journal of Natural Products 60: 1251-1260.

Riba M, Kiss-Sziksza A, Gonda S, Parizsa P, Déák B, Török P, Vasas G (2020) Chemotyping of terrestrial Nostoc-like isolates from alkali grassland areas by non-targeted peptide analysis. Algal Research 46: 101798.

Rippka R, Deruelles J, Waterbury JB, Herdman M, Stanier RY (1979) Generic assignments, strain histories and properties of pure cultures of cyanobacteria. Microbiology 111: 1- 61.

Romay C, Ledon N, Gonzalez R (1999) Phycocyanin extract reduces leukotriene B4 levels in arachidonic acid-induced mouse ear inflammation test. Journal of Pharmacy and Pharmacology 51(5): 641-642.

Safari R, Raftani Amiri Z, Esmaeilzadeh Kenari R (2020) Antioxidant and antibacterial activities of C-phycocyanin from common name Spirulina platensis. Iranian Journal of Fisheries Sciences 19(4): 1911-1927.

Sami N, Ahmad R, Fatma T (2021) Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2 Biomedical Journal 44(1) 54-62.

Saurav K, Macho M, Kust A, Delawská K, Hájek J, Hrouzek P (2019) Antimicrobial activity and bioactive profiling of heterocytous cyanobacterial strains using MS/MS-based molecular networking. Folia Microbiologica 64(5): 645-654.

Schaeffer DJ, Krylov VS (2000) Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicology and Environmental safety 45(3):208-27.

Schwartz J, Shklar G, Reid S, and Trickler D (1988) Prevention of experimental oral cancer by extracts of Spirulina-Dunaliella algae. Nutrition and Cancer 11 (2): 127-134.

Seddek NH, Fawzy MA, El-Said WA, Ahmed MMR (2019) Evaluation of antimicrobial, antioxidant and cytotoxic activities and characterization of bioactive substances from freshwater blue-green algae. Global Nest Journal 21(3): 328-336.

Senousy HH, Abd Ellatif S, Ali S (2020) Assessment of the antioxidant and anticancer potential of different isolated strains of cyanobacteria and microalgae from soil and agriculture drain water. Environmental Science and Pollution Research 27: 18463–18474.

Shi SR, Cote RJ, Taylor CR (1999) Standardization and further development of antigen retrieval immunohistochemistry: strategies and future goals. Journal of Histotechnology 22(3):177-92.

Shishido TK, Popin RV, Jokela J, Wahlsten M, Fiore MF, Fewer DP, Herfindal L, Sivonen K (2020) Dereplication of natural products with antimicrobial and anticancer activity from Brazilian cyanobacteria. Toxins 12(1):12.DOI: 10.3390/toxins12010012.

Singh IP, Milligan KE, Gerwick WH (1999) Tanikolide, a toxic and antifungal lactone from the marine cyanobacterium Lyngbya majuscula. Journal of Natural Products 62(9):1333-5.

Singh SM, Elster JOSEF (2007) Cyanobacteria in Antarctic lake environments. In: Algae and cyanobacteria in extreme environments. Springer, Dordrecht Pp. 303-320.

Singh U, Singh AK, Asthana RK (2021a) Bioactive molecules from microalgae and constraints in commercialization. Natural Bioactive Compounds Pp. 143-164.

Singh U, Singh P, Singh AK, Kumar D, Tilak R, Shrivastava SK, Asthana RK (2021b) Identification of antifungal and antibacterial biomolecules from a cyanobacterium, Arthrospira platensis. Algal Research 54:102215.

Smetana S, Sandmann M, Rohn S, Pleissner D, Heinz V (2017) Autotrophic and heterotrophic microalgae and cyanobacteria cultivation for food and feed: life cycle assessment. Bioresource Technology 245: 162-170.

Spoehr HA, Milner HW (1949) The chemical composition of Chlorella; effect of environmental conditions. Plant physiology 24(1):120.

Sridhar K, Inbaraj BS, Chen BH(2021) Recent developments on production, purification and biological activity of marine peptides. Food Research International 147: p.110468.

Srivastava VC, Manderson GJ, Bhamidimarri R (1999) Inhibitory metabolites production by the cyanobacterium Fischerella muscicola. Microbiological Research 153(4):309-17.

Stanier G (1988) Fine structure of cyanobacteria. Methods in Enzymology 167:157-172.

Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, Mattern M, Gerwick WH, Jacobs RS, Marshall LA (2002) The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore.
Stratmann K, Moore RE, Bonjouklian R, Deeter JB, Patterson GM, Shaffer S, Smith CD, Smiika TA (1994) Welwitidolionones, unusual alkaloids from the blue-green algae *Hapalosiphon welwitschii* and *Westiellia antarctica*. Relationship to fischeridinones and hapalindoles. Journal of the American Chemical Society 116(22):9935-9942.

Sturdy M, Krunic A, Cho S, Franzblau S, Orjala J (2010) Eucapsitrione, an anti-Mycobacterium tuberculosis anthraquinone derivative from the cultured freshwater cyanobacterium *Eucapsis sp.* Journal of natural products 73(8):1441-3.

Tang J, Jiang D, Luo Y, Liang Y, Li L, Shah MMR, Daroch M (2018) Potential new genera of cyanobacterial strains isolated from thermal springs of western Sichuan, China. Algal Research 31: 14-20.

Thajuddin N, Subramanian G (2005) Cyanobacterial biodiversity and potential applications in biotechnology. Current Science 10:47-57.

Tokuda H, Nishino H, Shirahashi H, Murakami N, Nagatsu A, Sakakibara J (1996) Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium *Phormidium tenue*. Cancer Letter 104: 91-95.

Trimurtulu G, Ohtani I, Patterson GM, Moore RE, Corbett TH, Valeriote FA, Demchik L (1994) Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga *Nostoc* sp. strain GSV 224. Journal of the American Chemical Society 116(11):4729-37.

Troschl C, Fritz I, Sodnikar K, Drosg B (2017) Contaminations in mass cultivation of cyanobacteria: Highly resilient Colpoda steinii leads to rapid crash of *Synechocystis* sp. cultures and is inhibited by partially anoxic conditions. Algal research 28: 229-234.

Uma VS, Gnanasekaran D, Lakshmanan U, Dharmar P (2020) Survey and isolation of marine cyanobacteria from eastern coast of India as a biodiesel feedstock. Biocatalysis and Agricultural Biotechnology 24: 101541.

Vanlalveni C, Rajkumari K, Biswas A, Adhikari PP, Lalfakzuala R, Rokhum L (2018) Green synthesis of silver nanoparticles using Nostoc linckia and its antimicrobial activity: a novel biological approach. BioNanoScience 8(2): 624-631.

Vasudevan S, Arulmoorthy MP, Suresh R (2020) Isolation, purification and structural elucidation of secondary metabolites from *Microcystis aeruginosa* bloom from *Muttukada estuary* and its in vitro antibacterial, antioxidant and anticancer potency. South African Journal of Botany 132: 59-67.

Verma E, Mishra AK, Singh AK, Singh VK (2016) Structural elucidation and molecular docking of a novel antibiotic compound from cyanobacterium *Nostoc* sp. MGL001. Frontiers in Microbiology 29(7):1899.

Volk RB, Farkert FH (2006) Antialgal, antibacterial and antifungal activity of two metabolites produced and excreted by cyanobacteria during growth. Microbiological Research 161(2):180-6.

WHO (2017) Global priority list of Antibiotic resistant bacteria to guide research discovery and developments of new antibiotics.

Wright AD, Papendorf O, König GM (2005) Ambigol C and 2, 4-Dichlorobenzoic Acid, Natural Products Produced by the Terrestrial Cyanobacterium *Fischerella ambiguia*. Journal of Natural Products 68(3):459-461.

Xiong C, O’Keefe BR, Byrd RA, McMahon JB (2006) Potent anti-HIV activity of scytovirin domain 1 peptide. Peptides 27(7):1668-75.

Xu HL, Kitajim C, Ito H, Miyazaki T, Bab M, Okuyam T (2012) Antidiabetic effect of polyphenols from brown alga *Ecklonia kurome* in genetically diabetic KK-Ay mice, Pharmaceutical Biology 50: 393–400.

Yamaguchi M, Ogawa T, Muramoto K, Kamiyo Y, Jimbo M, Kamiya (1999) Isolation and characterization of a mannan-binding lectin from the freshwater cyanobacterium (blue-green algae) *Microcystis viridis*. Biochemical and Biophysical Research Communications 265(3):703-8.

Yoon SH, Lee YM, Kim JE, Lee SH, Lee JH, Kim JY, Jung KH, Shin YC, Keasling JD, Kim SW (2006) Enhanced lycopene production in *Escherichia coli* engineered to synthesize isopentenyl diphosphate and dimethylallyl diphosphate from mevalonate. Biotechnology and Bioengineering 94(6):1025-32.

Yücer TD, Beyatli Y, Pabuçcu K (2018) The antiproliferative and antimicrobial effects of cultivated *Anabaena circinalis* Rabenhorts ex Bornet and Flahault and *Nostoc entophytum* Bornet and Flahault. Tropical Journal of Pharmaceutical Research 17(8): 1571-1577.

Zaki S, Merican F, Muangmai N, Convey P, Broady P (2020). Discovery of microcystin-producing *Anagnostidinema pseudacutissimum* from cryopreserved Antarctic cyanobacterial mats. Harmful algae 93: 101800.